- Part of a plan to cut opioid usage among its customers by 25% by 2019, Cigna (NYSE:CI) will no longer cover OxyContin as a preferred option on the insurer's group commercial drug list, effective Jan. 1.
- The company has signed a value-based contract with Collegium Pharma (COLL +0.9%) for the drug Xtampza ER, an oxycodone equivalent with abuse deterrent properties.
- Source: Press Release